Table 5.
Pharmacokinetic parameters of galgravin following single oral and intravenous administration to rats (mean ± SD, n = 6).
| Parameters | Oral administration (20 mg/kg) | Intravenous (2 mg/kg) |
|---|---|---|
| AUC(0 − t) (h ng/mL) | 314.25 ± 179.84 | 369.56 ± 66.06 |
| AUC(0 − ∞) (h ng/mL) | 315.75 ± 179.70 | 371.36 ± 66.59 |
| MRT(0 − t) (h) | 7.59 ± 1.67 | 1.27 ± 0.19 |
| MRT(0 − ∞) (h) | 7.80 ± 1.75 | 1.34 ± 0.21 |
| T 1/2z (h) | 3.99 ± 2.08 | 1.96 ± 0.80 |
| T max (h) | 2.08 ± 1.56 | 0.03 ± 0.00 |
| C max (ng/mL) | 48.42 ± 37.66 | 332.80 ± 63.59 |
| F (%) | 8.5 | — |
AUC: area under the concentration-time curve; MRT: mean residence time; T1/2z: elimination half-life; Cmax: maximum concentration; Tmax: time of peak concentration; F: absolute bioavailability.